NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

NovaBridge Biosciences announced updated Phase 1b data for givastomig, a CLDN18.2 x 4-1BB bispecific antibody, showing an objective response rate of 79% and median progression-free survival of 16.9 months in first-line metastatic gastroesophageal adenocarcinoma. The company selected the 8 mg/kg dose for registrational development with FDA alignment on Phase 3 study design, supported by Orphan Drug and Fast Track Designations.